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Asymmetric dimethylarginine (ADMA) is an endogenous
inhibitor of nitric oxide synthase (NOS) and has been
implicated in endothelial dysfunction. ADMA is metabo-
lized by the enzyme dimethylarginine dimethylaminohy-
drolase (DDAH), with DDAH2 representing the
predominant endothelial DDAH isoform. Symmetric
dimethylarginine (SDMA), also originating from arginine
methylation by protein arginine methyltransferases, is an
inhibitor of intracellular arginine uptake. In both, chronic
pulmonary hypertensive rats and patients suffering from
idiopathic pulmonary arterial hypertension (IPAH; NYHA
class III), a marked increase in plasma ADMA and SDMA
levels as well as tissue levels of asymmetric and symmetric
dimethylated proteins was observed. Moreover, when
comparing lung tissue from pulmonary hypertensive rats
and IPAH patients to corresponding normal lung tissue,
expression of DDAH2 was found to be reduced at both,
the mRNA and the protein level, with no significant
changes in DDAH1 expression. These findings were fur-
ther supported by demonstrating a decrease in DDAH2
function in the experimental pulmonary hypertension
model. Immunohistochemistry in human and rat control
tissue demonstrated both isoforms of DDAH in the
endothelial layer and the in the alveolar epithelium. In
contrast, in pulmonary hypertensive tissue, the immuno-
reactivity of DDAH2 in pulmonary endothelium was sig-
nificantly decreased compared to DDAH1. Therefore,
altogether we can conclude that enhanced dimethyl-
arginine levels may contribute to vascular abnormalities
in pulmonary arterial hypertension. Suppression of
endothelial DDAH2 expression and function represent an
important underlying mechanism.
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